Human cathelicidin antimicrobial peptide
PRODUCT PROFILE
LL-37
£59.00
LL-37 is human cathelicidin antimicrobial peptide. Researchers examine it in relation to innate host defence, microbial membranes, inflammation and wound signalling.
Why it is distinct
Direct antimicrobial membrane activity separates it from immune regulators such as KPV or thymosin alpha-1.
- Evidence stageEarly human evidence
- AvailabilityUnavailable
- Batch recordOpen COA
- DispatchConfirmed at checkout
Out of stock
Ask about availabilitySUGGESTED ADD-ONS
Useful additions, clearly shown.
Suggestions are organised by vial format and catalogue context. They are not combined-use guidance or personal-use advice.
-
Specification review
Bacteriostatic Water
Price range: £4.49 through £8.9910 mL | 3 mLBatch file pendingA laboratory supply with two volume variants, not a peptide or biologically active comparison material.
Available · select size for stockAdd to basket This product has multiple variants. The options may be chosen on the product page -
Preclinical
BPC-157
£32.99Batch COA availableBPC-157 is mainly discussed around stomach and local tissue-repair models. TB-500 is instead studied for actin, cell movement…
Available · 30 in stockAdd to basket -
Preclinical
TB-500
£32.99Batch COA availableTB-500 is discussed as a fragment-like repair material, while thymosin beta-4 is the full natural protein and BPC-157…
Available · 30 in stockAdd to basket
PRODUCT INFORMATION
Clear first. Detailed when needed.
What this material is+
LL-37 is human cathelicidin antimicrobial peptide. Researchers examine it in relation to innate host defence, microbial membranes, inflammation and wound signalling.
Research focus+
Researchers study how it interacts with microbes, inflammation and wound repair. Its effects are complex—it may help defence in some settings but can also increase inflammation in others.
How the mechanism differs+
Can disrupt microbial membranes and also signal through host immune pathways; activity is context- and concentration-dependent.
Evidence and limitations+
Strong mechanistic and preclinical literature with limited early clinical exploration; inflammatory effects can be bidirectional.
Testing and batch documentation+
Verified batch documents are available for review.
RESEARCH PROFILE
Understand the distinction.
Researchers study how it interacts with microbes, inflammation and wound repair. Its effects are complex—it may help defence in some settings but can also increase inflammation in others.
Can disrupt microbial membranes and also signal through host immune pathways; activity is context- and concentration-dependent.
Direct antimicrobial membrane activity separates it from immune regulators such as KPV or thymosin alpha-1.
Strong mechanistic and preclinical literature with limited early clinical exploration; inflammatory effects can be bidirectional.
Educational research context only. This information is not dosage, administration or personal-use guidance.
CONTINUE EXPLORING
Related research perspectives.
Selected for useful comparison across neighbouring or contrasting research areas—not as combined-use guidance.
-
Established
Thymosin Alpha-1
£69.0010 mgBatch COA availableAn immune-response modulator with human clinical literature, distinct from LL-37’s direct antimicrobial activity.
UnavailableAsk about availability -
Preclinical
KPV
Price range: £27.47 through £29.9910 mgBatch COA availableA minimal anti-inflammatory alpha-MSH fragment rather than an antimicrobial peptide such as LL-37.
Available · select size for stockAdd to basket This product has multiple variants. The options may be chosen on the product page